Cardiogeni Plc Set to List on AQSE as It Pioneers Next-Generation Cardiac Regenerative Medicine

Proactive - Interviews for investors

Cardiogeni Plc Executive Chairman Darrin Disley joined Steve Darling from Proactive to discuss the company’s listing on the AQSE Growth Market under the ticker CGNI. Founded by Nobel Laureate Professor Sir Martin Evans, Cardiogeni is developing a groundbreaking new class of cellular therapies aimed at treating irreversible conditions such as heart failure. At the forefront of its innovations is an advanced engineered cell therapy designed specifically for patients undergoing coronary artery bypass grafting surgery. This novel treatment utilizes a unique allogeneic cell type engineered for cardiac regeneration, aiming to restore damaged heart tissue, improve function, and significantly enhance both life expectancy and quality of life. The therapy is backed by a robust intellectual property portfolio of approximately 100 international patents and trademarks. The company has received regulatory approval in a European Union member state to initiate a randomized controlled trial, with patient dosing already underway. Interim data is expected within 18 months, providing key insights into the therapy’s potential impact. Heart failure affects one in four individuals worldwide and currently has no cure. However, results from an EU Phase II clinical trial have demonstrated statistically significant improvements in heart function, reduced cardiac scarring, and enhanced quality of life, positioning Cardiogeni’s therapy as a promising solution to this global health challenge. As Cardiogeni moves toward its AQSE listing, the company is establishing itself as a leader in cardiac regenerative medicine, leveraging cutting-edge science to address one of the most pressing unmet medical needs. #proactiveinvestors #cardiogeniplc #heartfailure #cardiac #Biotech #RegenerativeMedicine #HeartFailure #ClinicalTrials #AQSE #StemCellTherapy #MedicalInnovation #Investing #Healthcare